

# Online Only Lectures - Management of AIDS-Related Opportunistic Infections II

Speaker: Henry Masur, MD

**IDBR**  
**INFECTIOUS DISEASE BOARD REVIEW**  
**AUGUST 20-24**  
**2022**

**Management of AIDS-Related Opportunistic Infections II**

Henry Masur, MD  
Bethesda, Maryland

6/15/2022

**IDBR**  
**INFECTIOUS DISEASE BOARD REVIEW**  
**AUGUST 20-24**  
**2022**

**Disclosures of Financial Relationships with Relevant Commercial Interests**

- None

**Question #1**

A 50-year-old male has HIV (CD4=40 cells/uL and HIV viral load =600,000 copies/uL) has central nervous system toxoplasmosis documented by a compatible CT of the head and a positive CSF PCR for toxoplasma.

The patient also has cryptosporidiosis with 4 stools per day plus considerable nausea and thus has limited food intake.

The pharmacy cannot obtain sulfadiazine or pyrimethamine.

The best option for therapy of the toxoplasmosis would be:

- A. Atovaquone
- B. Clindamycin plus primaquine
- C. Trimethoprim-Sulfamethoxazole
- D. Azithromycin plus Doxycycline
- E. Nitazoxanide

**Answer #1**

A 50-year-old male has HIV (CD4=40 cells/uL and HIV viral load =600,000 copies/uL) has central nervous system toxoplasmosis documented by a compatible CT of the head and a positive CSF PCR for toxoplasma.

The patient also has cryptosporidiosis with 4 stools per day plus considerable nausea and thus has limited food intake.


The pharmacy cannot obtain sulfadiazine or pyrimethamine.


The best option for therapy of the toxoplasmosis would be:

- A. Atovaquone
- B. Clindamycin plus primaquine
- C. **Trimethoprim-Sulfamethoxazole**
- D. Azithromycin plus Doxycycline
- E. Nitazoxanide

**Question #2**

- A 39-year-old female from Brazil presents to an ER with a seizure.
  - Her CT scan is shown
  - Her HIV serology is positive
  - CD4 = 20/uL
  - VL = 100,000 copies/uL
- It is thought to be unsafe to perform an LP.
- She is started on sulfadiazine and pyrimethamine.
- ARVs are held until her acute problem is under control.
- After 10 days, she has not improved and a brain biopsy is performed (see image).





**Question #2**

What is the most likely diagnosis?

- A. Toxoplasmosis
- B. Cysticercosis
- C. Leishmaniasis
- D. Trypanosomiasis
- E. Acanthamoeba

**Answer #2**

- A 39-year-old female from Brazil presents to an ER with a seizure.
  - Her CT scan is shown
  - Her HIV serology is positive
  - CD4 = 20/uL
  - VL = 100,000 copies/uL
- It is thought to be unsafe to perform an LP.
- She is started on sulfadiazine and pyrimethamine.
- ARVs are held until her acute problem is under control.
- After 10 days, she has not improved and a brain biopsy is performed (see image).

• What is the most likely diagnosis?


- A. Toxoplasmosis
- B. Cysticercosis
- C. Leishmaniasis
- D. **Trypanosomiasis**
- E. Acanthamoeba

**Trypanosoma cruzi**  
**Blood Smear and CSF**

Badero et al. AIDS THERAPY, 4th Ed

**Toxoplasmosis**

**Ctenodactylus Gondii**





### Incidence of Toxoplasmosis

- Seroprevalence in General Population
  - US-20%
  - Some areas of Europe, Africa: 80%
- Clinical disease common (30%) before ART and chemoprophylaxis
- Disease "never" occurs in seronegative patients except
  - Acute infection
  - Insensitive assay
  - Loss of ability to make antibody

### Transmission of Toxoplasma

- **Feline feces (cats, but also lions etc)**
  - Oocysts begin to be excreted 20 - 24 days post infection
  - Excretion persists 7 - 21 days
- **Rare Meat (Lamb>Beef>Pork)**
- **Unusual**
  - Raw shellfish, goat milk (reported 2009-2010)
  - Iatrogenic
    - Transfusion/Needle injury/transplant
- **Congenital**
  - Acute acquisition by mother during gestation
  - Chronic infection in immunosuppressed mother



### Evaluation of CNS Mass Lesions in Patients with HIV/AIDS

**Toxoplasmosis**

Lymphoma

Tuberculosis

Fungus

Nocardia

Bacterial

Syphilis

Kaposi

Chagoma

Glioblastoma

**Radiologic Results**

Non-specific although certain features suggestive  
Look for Extra CNS lesions for biopsy

**Laboratory Studies to Perform**

Serology: Toxo IgG, Toxo PCR

Serum Crypt Ag and Histo ag

Blood culture - AFB, fungus

CSF - Crypt Ag

PCR (EBV, CMV, Toxo)

Urine - Histo Ag


**Response to Empiric Therapy**

## Empiric Diagnosis of CNS Toxo

- When Initiating Therapy
  - Compatible CT or MR *plus*
  - CD4 Count <100 cells/uL *plus*
  - Toxo IgG antibody positive *plus*
  - Not on TMP-SMX prophylaxis
- Post Initiation of Therapy
  - Radiologic and Clinical Response within 2 weeks

## Time to Neurologic Response for CNS Toxo

35 CNS Toxo Patients Treated with Clindamycin - Pyrimethamine



Luft BJ, NEJM 1993

## Definitive Diagnosis of Cerebral Toxoplasmosis

- Brain biopsy
- Serum PCR
- CSF PCR

## Therapy for Cerebral Toxoplasmosis

- Preferred Regimen
  - Sulfadiazine plus pyrimethamine plus leucovorin (PO only)
    - Expensive, not universally available
  - Trimethoprim-sulfamethoxazole (PO or IV)
- Alternative Regimens
  - Clindamycin plus pyrimethamine
  - Atovaquone +/- Pyrimethamine

## Adjunctive Therapies for CNS Toxoplasmosis

- Corticosteroids
  - Not routine
  - Only if increased intracranial pressure/symptoms/signs
- Anticonvulsants
  - Not routine
  - Only after first seizure

## Primary Prevention of Toxoplasmosis in Patients with HIV

- Indication
  - Positive IgG and CD4<100 cells/uL
- Drugs
  - First Choice
    - TMP-SMX (one ds qd)
  - Alternatives
    - Dapsone-Pyrimethamine
    - Atovaquone + Pyrimethamine

# Online Only Lectures - Management of AIDS-Related Opportunistic Infections II

Speaker: Henry Masur, MD

## Primary Prevention of Toxoplasmosis in PLWH

- For patients with CD4<200 who are on TMP-SMX or atovaquone for PCP prophylaxis
  - Nothing more is needed
- For patient on Aerosol Pentamidine or Dapsone for PCP prophylaxis
  - If on dapsone: add pyrimethamine
  - If on Aerosol pentamidine: not protected-
    - Consider switching to atovaquone if seropositive for toxo

## Mycobacteria Species

- *M. tuberculosis*\*
  - *M. bovis*
  - *M. africanum*
- **Mycobacteria Other Than TB (MOTT)**
  - *M. avium complex*\*
  - *M. kansasii*
  - *M. hemophilum*
  - *M. genavense*
  - *M. terrae*
  - *M. scrofulaceum*
  - *M. xenopi*

## Question #4

A 45-year-old male with HIV (CD4<10 cells/cc3, VL> 100k) has been taking TMP-SMX and Efavirenz-Tenofovir-Emtricitabine only intermittently.

For the past 3 weeks he has had a low grade fever, mild weight loss, and a lesion which is shown on the next slide.

Aspiration of the lesion showed many AFB rods, non branching, but after 6 weeks nothing grew.

The lesion is to be aspirated again.

See next slide



## Question #4

What advice do you give the lab and hospital epi?

- A. This should grow at 37°C
- B. This should grow on conventional TB culture media
- C. This most likely was acquired by acupuncture or some other manipulation.
- D. This is treatable with trimethoprim-sulfamethoxazole
- E. This can be cultured only at 32°C with iron enriched medium

## Answer #4

What advice do you give the lab and hospital epi?

- A. This should grow at 37°C
- B. This should grow on conventional TB culture media
- C. This most likely was acquired by acupuncture or some other manipulation.
- D. This is treatable with trimethoprim-sulfamethoxazole
- E. **This can be cultured only at 32°C with iron enriched medium**

# Online Only Lectures - Management of AIDS-Related Opportunistic Infections II

Speaker: Henry Masur, MD

## Tuberculosis and HIV

Susan Dorman has reviewed this in detail

- Major Issues for Boards
  - Most of US cases were acquired outside of US
  - Positive PPD = 5mm for PWH
  - Treat HIV infected patient with close contact for active TB regardless of PPD/IGRA result
- (unlike HIV negative exposed person who are given prophylaxis only if IGRA or ppd pos with 5mm)

## Therapy for HIV Positive Patients With Active TB

- Always start TB therapy first, and then start ART later depending on CD4 count and severity of disease
  - If CD4 < 50, start ART within 2 weeks
  - If CD4 > 50, start within 8 weeks
- Only use regimens to treat active TB if the drugs are DAILY
- Failing Therapy?
  - Consider IRIS vs drug resistance or non adherence
- Treatment of Drug Resistant TB
  - Too complicated for exam!

## Non Tuberculous Mycobacterial Infections in HIV Infected Patients

You Need Microbiologic or Epidemiologic Clue on Exam!

- **Avium complex** Dissemination
- **Hemophilum** Cutaneous abscesses
- **Bovis** Adenitis, Dissemination
- **BCG (Bovis)** Dissemination
- Genovense Dissemination
- Scrofulaceum Adenitis, Dissemination
- Xenopi Lung nodules or infiltrates
- Malmoense Cavitory lung, CNS ring lesions
- Cheloniei Skin, Soft Tissue, Joint, Bone

## Mycobacterium Avium Complex

Confusing Terminology: Some Labs Are Identifying MAC Species Not Clear If There Is Clinical Benefit in Identifying

- M. avium
- M. intracellulare
- M. chimaera
- M. colombiense
- M. arosiense
- M. marseillense
- M. timonense
- M. vulneris
- M. yongonense

## Question #3

An HIV-infected patient is admitted to the hospital with three weeks of cough, fever, 25 lb weight loss, and anorexia. He is found to be HIV infected and to have a CD4 count = 10 cells/uL and VL = 500k

- His chest x-ray shows diffuse interstitial infiltrates
- BAL = PCP by immunofluorescence

Two weeks later while the patient is still in the hospital due to disposition issues, the lab reports

- Three blood cultures and the BAL are growing a mycobacterium
- Probe = Mycobacterium avium complex

What type of isolation is appropriate?

- A. None
- B. Droplet
- C. Respiratory
- D. Contact
- E. Contact and droplet

## Question #3

An HIV-infected patient is admitted to the hospital with three weeks of cough, fever, 25 lb weight loss, and anorexia. He is found to be HIV infected and to have a CD4 count = 10 cells/uL and VL = 500k

- His chest x-ray shows diffuse interstitial infiltrates
- BAL = PCP by immunofluorescence

Two weeks later while the patient is still in the hospital due to disposition issues, the lab reports

- Three blood cultures and the BAL are growing a mycobacterium
- Probe = Mycobacterium avium complex

What type of isolation is appropriate?

- A. **None**
- B. Droplet
- C. Respiratory
- D. Contact
- E. Contact and droplet

## Mycobacterium Avium Intracellulare Complex

- **Epidemiology**
  - Ubiquitous in dirt, animals etc
- **Transmission**
  - Respiratory via dust
  - GI via food, water
  - Person-to-person unlikely
  - Environmental isolates correlate poorly with human isolate

## Mycobacterium Avium Intracellulare

- **Risk factors**
  - CD4 < 50 or High VL
  - Colonization: GI / respiratory
- **Incidence pre ART: 20-40% (North America)**
  - Now declining with ART and probably non-ART related factors
- **Acute Disease: Clinical manifestations**
  - Fever, wasting, nodes, liver, spleen
  - Rare as cause of lung disease
  - Lab: Alk Phos, Hg, Albumen

## Mycobacterium Avium Intracellulare Diagnosis

- **Source of Isolates**
  - **Blood**
    - Bactec (7-14 days),
  - **Sputum/Stool/Urine**
    - Low predictive value
- **Lab Identification**
  - Specific DNA Probes for specimens/ cultures
  - MALDI-TOF

## MAC: Susceptibility Testing

Recommended for primary isolates

- **Validated CLSI** (Clinical Laboratory Standards Institute)
  - Clarithromycin
  - Amikacin
- **Other drug susceptibility results not clearly associated with clinical outcome**

## Treatment for MAC

- **Antiretroviral Therapy**
  - Start within 2 weeks of anti mac therapy
- **Specific Therapy**
  - Clarithro (or Azithro) + Ethambutol
    - Rifabutin optional 3<sup>rd</sup> drug: use if severe disease (“high burden of organisms”)
    - Beware drug interactions with clari or rifabutin

## Treatment for MAC

- **Response:**
  - Fever should decline within 2-4 weeks
  - Blood cultures should be negative in 2-4w
  - Repeat blood cultures only if symptoms
- **Stop chronic suppression:**
  - CD4 > 100 x 6M, asx and therapy >12 m

## Salvage Therapy for MAC Not For Boards

- No evidence-based standard
- Logical to be guided by in vitro susceptibility testing
  - Not standardized for MAC other than macrolides and amikacin
- Options
  - Amikacin, Ciproflox, Moxiflox, Mefloquine, Linezolid, Bedaquiline

## Primary MAC Prophylaxis 2021

- Primary prophylaxis against disseminated MAC disease is **NOT** recommended if ART initiated immediately
  - Primary MAC prophylaxis, if previously initiated, should be discontinued if person is on ART

## What Is This?



## Immune Reconstitution Inflammatory Syndrome

- Definition
  - Worsening manifestations or abrupt /atypical presentation of infection or tumor when ART started
  - Paradoxical-exacerbation of pre-existing infection or tumor
  - Unmasking-exacerbation of previously occult infection/tumor
- Timing
  - Few days to 6 months after ART initiated
  - Viral load drop more relevant than CD4 rise
    - (better lymphocyte function > number)

## Immune Reconstitution Inflammatory Syndrome

- Predictors
  - Pre therapy low CD4 or high VL
  - Prior OI or short therapy for OI
  - High pathogen load
- Outcome-Morbidity Can Be Severe
  - Obstructed bowel, biliary tract, ureter, bronchus
  - Myocarditis, meningeal inflammation/increased ICP, serositis (pleura, peritoneum, pericardium)

## Pathogens Commonly Associated with IRIS



- Mycobacterium avium complex
- Mycobacterium tuberculosis
- Cryptococcus neoformans
- Many others
  - CMV retinitis, HBV
  - Mucocutaneous HSV and VZV
  - PCP, Histo
  - PML
  - KS



### Examples of IRIS

PATHOGEN	NOMENCLATURE	TYPICAL CHARACTERISTICS OF THE DISEASE
<i>Mycobacterium tuberculosis</i>	TB-IRIS	Paradoxical exacerbation of TB
Nontuberculous mycobacteria (NTM)	NTM-IRIS	Mainly lymphadenitis, also pulmonary and abdominal diseases
Bacille Calmette-Guérin (BCG)	BCG-IRIS	Necrotizing regional lymphadenitis
<i>Mycobacterium leprae</i>	Leprosy-associated IRIS	Borderline and type 1 reactional state
<i>Cryptococcus neoformans</i>	C-IRIS	Mainly meningitis, also lymphadenitis
<i>Pneumocystis jirovecii</i>	Pneumocystosis-associated IRIS	Paradoxical exacerbation of pneumonitis
Cytomegalovirus (CMV)	CMV retinitis after ART or immune recovery uveitis	Acute retinitis after commencing ART or uveitis
JC polyomavirus	PML-IRIS	Multifocal leukoencephalopathy
Human herpesvirus 8	KS-IRIS	Rapid progression of existing and/or new KS lesions
Hepatitis B or C virus	Hepatitis B or C virus-associated IRIS (that may mimic DILI)	Hepatitis flare and/or liver enzyme elevation
Varicella-zoster virus		Dermatomal or multidermatomal zoster and rarely myelitis after ART
Herpes simplex virus		Herpes lesions with exaggerated inflammation and rarely myelitis or encephalitis after ART
<i>Molluscum contagiosum</i> virus	Inflammatory molluscum contagiosum	Inflamed molluscum lesions
<i>Malassezia</i> spp.	Inflammatory seborrheic dermatitis	Abnormally inflamed seborrheic dermatitis <small>Cecil Textbook French and Meirns)</small>

- ### Management of IRIS
- Reassess Diagnosis
    - Evaluate for concurrent, additional OIs and tumors
  - Treat IRIS
    - Continue ART
    - Treat identified pathogen-usual practice without data
    - NSAIDs or Corticosteroids
      - Prednisone 20-40mg qd x 4-8 weeks



- ### Life Threatening IRIS –How Would They Test for These?
- Unmasking
    - Unrecognized lymphadenitis due to TB, MAC, Fungi
    - Unrecognized cryptococcal meningitis
    - Unrecognized CMV retinitis
    - Inflammation of Kaposi sarcoma skin lesion
    - Pulmonary infiltrates due to PCP, fungi, TB
  - Exacerbation of Crypt Meningitis- Increased intracranial pressure
    - New focal findings
  - Transaminase Flair in Patient with Untreated HBsAg or HBcoreAb
    - Transaminase flair due to HBV
  - Exacerbation of previously treated CMV retinitis, PCP, TB

## Fungal Diseases in HIV-Infected Persons

- Candidiasis
- Cryptococcosis
- Histoplasmosis
- Coccidiomycosis
- Talaromyces

## Skin Lesions HIV-Difficult to Distinguish



## Importance of HIV Associated Cryptococcosis

- Prevalence
  - Pre ART in United States- 5 – 8% of patients
  - More common in Sub-Saharan Africa
    - 15% of AIDS related deaths
  - Less common in current era in US
- CD4 Count at Onset
  - <100 cells/uL in 90% of patients

## HIV-Related Cryptococcal Meningitis

- Clinical Presentation
  - CNS manifestations are usually subacute (median 2 weeks)
  - Classic neck stiffness and photophobia only occur in 25%
  - Many cases are disseminated when initially diagnosed-any organ
    - e.g. May mimic PCP or present as lobar consolidation
  - Crypt IRIS is typically more acute than active infection
- Meningeal involvement may initially be asymptomatic
  - Encephalopathic manifestations usually due to high ICP

## Diagnosis of Cryptococcal Disease

- CSF
  - Often minimal abnormalities with lymphocyte pleocytosis
  - Opening pressure >20-25cm H2O in 60-80% of patients
- Crypt Antigen
  - Highly sensitive in serum and CSF
  - CSF crypt ag can be positive months before symptomatic disease
- Blood Culture positive
  - 60% of patients with clinical meningitis
  - Growth in < 7 days

## Antigen Tests for Cryptococcal Disease

- Blood, Serum, Plasma, CSF:
  - Antigen Latex Agglutination or
  - Enzyme Linked Immunoassay (EIA) or
- Cryptococcal Lateral Flow Assay (IMMY LFA)
  - Dipstick test for whole blood/serum/plasma and CSF
  - Four-fold higher titers than Latex Aggl or EIA
  - High titers suggest (1:160) or highly suggest (1:640) dissemination

## PCR Tests for Cryptococcal Disease C. neoformans and C. gatti

- PCR for CSF
  - Screening test available in multiplex assays
    - False positives and false negatives (!!) reported
    - **Simultaneous antigen test should be performed** if cryptococcal meningitis is suspected and PCR is negative
  - May be useful for distinguishing
    - IRIS (PCR neg)
    - Relapse (PCR positive)

## Therapy of Cryptococcal Meningitis

Liposomal Ampho B 3-4 mg/kg qd plus Flucytosine* 25 mg/kg QID	→	2 weeks- Induction
Fluconazole <del>200</del> 800 mg po qd	→	8 weeks- Consolidation
Fluconazole 200 mg po qd	→	≥ 52 weeks-Maintenance

## Therapy of Cryptococcal Meningitis

Liposomal Ampho B 3-4 mg/kg qd plus Flucytosine* 25 mg/kg QID	→	2 wks- Induction
Fluconazole <del>200</del> 800 mg po qd	→	8 wks- Consolidation
Fluconazole 200 mg po qd	→	≥ 52 wks**Maintenance

\*5FC Associated with Earlier sterilization CSF  
 Fewer relapses  
 Improved survival

Flucon 800mg consolidation  
 \*Cidal  
 \*Fewer relapses 800 vs 400

\*\* Stop after 12 m total therapy if  
 CD4 >100- 150 x >3m  
 Asymptomatic  
 VL <50 copies

## Question #5

Patient presents with cryptococcal meningitis, severe headache, and opening pressure >25 cm H2O on day 1 of therapy

Which of the following would you initiate if the CNS symptoms persist on day 2

- Dexamethasone
- Acetazolamide
- Mannitol
- Lumbar puncture to remove fluid
- Lumbar puncture for repeat diagnostic studies and MRI to assess for a second, concurrent infectious or neoplastic process

## Answer #5

Patient presents with cryptococcal meningitis, severe headache, and opening pressure >25 cm H2O on day 1 of therapy

Which of the following would you initiate if the CNS symptoms persist on day 2

- Dexamethasone
- Acetazolamide
- Mannitol
- Lumbar puncture to remove fluid**
- Lumbar puncture for repeat diagnostic studies and MRI to assess for a second, concurrent infectious or neoplastic process

## Elevated CSF Pressure

- 75% of patients have Opening Pressure >20 cm CSF
  - Abnormal = >25 cm CSF
  - Left lateral decubitus, flat position
- Symptoms
  - Blurred vision, confusion, obtundation
- Management: IF symptomatic and >25cm
  - Remove volume to reduce pressure by half or <20cm H2O
  - Continue LPs daily for symptomatic patients until stable for at least 2 days
  - Shunt if regular LPs required for "many" days
- Not routinely recommended
  - Corticosteroids, Mannitol, Acetazolamide

# Online Only Lectures - Management of AIDS-Related Opportunistic Infections II

Speaker: Henry Masur, MD

## Consolidation Therapy

- **At two weeks**
  - Perform LP and repeat CSF culture
  - Success= Substantial clinical improvement AND negative CSF culture
    - Persistent CSF crypt ag is not indicative of failure
  - If patient is not symptomatically improved
    - Continue induction regimen until CSF culture confirmed as negative
      - (or use flucytosine +fluconazole as outpatient)
- **Continue consolidation until**
  - ART started
  - CSF culture negative

## Monitoring Therapy for Cryptococcal Meningitis

- **During Therapy**
  - “Monitoring serum or CSF CrAg titers is of no value in determining initial response to therapy and is not recommended (AII)”—NIH CDC IDSA Guideline
  - Monitor 5FC levels after dose 3 or 5
  - Positive CSF culture at 2 weeks indicates need for higher dose fluconazole during consolidation
  - Negative serum or CSF Ag is NOT required for termination of therapy

## Commonly Asked Questions

- **Liposomal Amphotericin B Induction for < 14 days**
  - Not recommended and not for boards
- **Fluconazole based regimens in US As Initial Rx**
  - No
- **Amphotericin plus Fluconazole induction**
  - Not for boards and not recommended in US

## When To Start ART

- **4-6 weeks after initiation of antifungal therapy** for meningitis
  - May have to defer for patients with severe disease
  - When to start for non CNS disease less clear
- **Monitor for IRIS**

## Asymptomatic Cryptococcal Antigenemia

(Pre-emptive Therapy for Crypt Ag +/-Low CD4)




- **Recommendation:**
  - Screen patients with CD4 < 100
    - Frequency: 2.9% if CD4 <100, 4.3% if CD4 < 50
  - Positive serum ag predicts development of active disease
- **If Positive: Perform LP and Blood Cultures to determine Rx**
  - If CSF positive or serum LFA is  $\geq 640$ 
    - Treat like crypt meningitis/disseminated (Ampho/5FC)
  - If CSF negative
    - Treat with fluconazole 400mg or 800mg x6 months

IDSA OI Guidelines for Crypt 2021

## Flucytosine


- **Oral only form available in US**
  - 25mg/kg po q6h
- **Toxicities**
  - Marrow suppression, hepatitis, diarrhea
- **Monitoring**
  - Serum level drawn after 3-5 doses
  - Renal elimination-
    - monitor renal function
  - Maintain 2 hr peak at 30-80ug/ml

**Other Fungal Diseases That Are Covered Elsewhere in IDBR**

- Look for questions on patients with HIV and ....
  - Histoplasmosis 
  - Coccidiomycosis 
  - Talaromycosis 


**Histoplasmosis**

- **Clinical Presentation**
  - CD4>200 cells/uL
    - Focal disease like immunocompetent
  - CD4<200 cells/uL
    - Disseminated disease:
      - Fever, weight loss, fatigue, hepatosplenomegaly
      - Meningitis, Septic Shock, GI manifestations also common
- **Diagnosis**
  - Antigen detection
  - BAL antigen also useful
  - Cultures useful but....takes several weeks to grow



**Talaromyces – Formerly Penicilliosis marneffii**

- Rarely if Ever Seen in US
- Common in Asia transmitted by Bamboo Rat or Abiotically
- Serum antigen test (research) sensitive and specific
- Treat with Ampho or Itraconazole



**CMV**

**Non ARS Question**

In an HIV positive patient (CD4 count = 50 cells/uL), a positive CMV PCR test of which of the following specimens would be MOST suggestive that CMV is the cause of end organ disease:

- Esophageal biopsy to diagnose CMV esophagitis
- Colonic biopsy to diagnose CMV colitis
- Bronchoalveolar lavage to diagnose CMV pneumonia
- Blood to diagnose CMV retinitis
- CSF to diagnose CMV encephalitis

**Non ARS Question**

In an HIV positive patient (CD4 count = 50 cells/uL), a positive CMV PCR test of which of the following specimens would be MOST suggestive that CMV is the cause of end organ disease:

- Esophageal biopsy to diagnose CMV esophagitis
- Colonic biopsy to diagnose CMV colitis
- Bronchoalveolar lavage to diagnose CMV pneumonia
- Blood to diagnose CMV retinitis
- CSF to diagnose CMV encephalitis

Non ARS Question

In an HIV positive patient (CD4 count = 200 cells/uL), a positive CMV PCR test of which of the following specimens would be MOST suggestive that CMV is the cause of end organ disease:

- A. Esophageal biopsy to diagnose CMV esophagitis
- B. Colonic biopsy to diagnose CMV colitis
- C. Bronchoalveolar lavage to diagnose CMV pneumonia
- D. Blood to diagnose CMV retinitis
- E. CSF to diagnose CMV encephalitis
- F. None of the above (ABIM never uses this option!!)

CMV Syndromes

CD4<50 and VL Positive In Almost All Cases

- Retinitis (30% of Patients Before ART)
- Colitis
  - Can lead to perforation
- Ventriculitis
  - Rapid cognitive decline with cranial nerve involvement
- Radiculopathy, Myelitis, Mononeuritis Multiplex, Guillain-Barre
- Esophagitis (uncommon)
- Adrenalitis (rare)
- Pneumonia (rare)

Diagnosis of HIV Related CMV Disease

- Serology
  - Disease unlikely if IgG seronegative
  - Rarely done
- Cytology
  - Rarely useful
- Biopsy
  - Helpful if many inclusions and substantial inflammation
- PCR
  - Correlates with CD4 Count
  - "Less than ideal" sensitivity and specificity for clinical disease

Diagnosis of HIV Related CMV Disease

- Serology
  - Disease unlikely if IgG seronegative
  - Rarely done
- Cytology
  - Rarely useful
- Biopsy
  - Helpful if many inclusions and substantial inflammation
- PCR
  - Correlates with CD4 Count
  - "Less than ideal" sensitivity and specificity for clinical disease

Clinical Presentation  
Rule Out Other Causes When Appropriate

Diagnosis of CMV Retinitis

- Funduscopic exam
  - Bilateral in 30% of untreated patients
  - Mustard and Ketchup
  - Necrosis of retina
  - Little vitreal inflammation
- PCR of blood not useful: 70% sensitive, very non specific
- Vitreal taps for diagnosis with PCR rarely necessary
  - Tap positive in 80% of cases

CMV Retinitis



# Online Only Lectures - Management of AIDS-Related Opportunistic Infections II

Speaker: Henry Masur, MD

## Therapy for CMV Retinitis

(Ganciclovir intraocular implant no longer available)

- Immediate sight-threatening lesions
  - ART
  - IV Ganciclovir or Valganciclovir 900 mg PO (bid x 14–21 days), then qd for at least 3-6 months plus
  - Intravitreal ganciclovir weekly over several weeks until lesion inactivity
    - Injections can be associated with infections or retinal detachment and hemorrhage
- Small peripheral lesions
  - ART
  - Oral valganciclovir for at least 3-6 months and immune reconstitution
  - +/- intravitreal ganciclovir

## Salvage Therapy for CMV Retinitis (Hard to Ask on Exam)

- Systemic Options
  - Ganciclovir higher dose
  - **Foscarnet IV**
  - Foscarnet IV plus Ganciclovir IV
  - Cidofovir IV
- Intraocular
  - Ganciclovir or Foscarnet

## Treatment of Other CMV Syndromes

- IV or Oral Ganciclovir or Foscarnet
- Duration hard to test
  - Colitis or Esophagitis
    - 21-42 days or until clinical resolution
  - Ventriculitis
    - Not certain: some would use ganciclovir plus foscarnet

Thank You